Short- and Long-term Central Action of Botulinum Neurotoxin Treatment in Laryngeal Dystonia
Open Access
- 28 June 2022
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 99 (11), e1178-e1190
- https://doi.org/10.1212/wnl.0000000000200850
Abstract
Background and Objectives Laryngeal dystonia (LD) is isolated task-specific focal dystonia selectively impairing speech production. The first choice of LD treatment is botulinum neurotoxin (BoNT) injections into the affected laryngeal muscles. However, whether BoNT has a lasting therapeutic effect on disorder pathophysiology is unknown. We investigated short-term and long-term effects of BoNT treatment on brain function in patients with LD. Methods A total of 161 participants were included in the functional MRI study. Statistical analyses examined central BoNT effects in patients with LD who were stratified based on the effectiveness and duration of treatment. Results Patients with LD who were treated and benefited from BoNT injections had reduced activity in the left precuneus compared with BoNT-naive and treatment nonbenefiting patients. In addition, BoNT-treated patients with adductor LD had decreased activity in the right thalamus, whereas BoNT-treated abductor patients with LD had reduced activity in the left inferior frontal cortex. No statistically significant differences in brain activity were found between patients with shorter (1–5 years) and longer (13–28 years) treatment durations. However, patients with intermediate treatment duration of 6–12 years showed reduced activity in the right cerebellum compared with patients with both shorter and longer treatment durations and reduced activity in the right prefrontal cortex compared with patients with shorter treatment duration. Discussion Our findings suggest that the left precuneus is the site of short-term BoNT central action in patients with LD, whereas the prefrontal-cerebellar axis is engaged in the BoNT response in patients with intermediate treatment duration of 6–12 years. Involvement of these structures points to indirect action of BoNT treatment on the dystonic sensorimotor network through modulation of motor sequence planning and coordination.This publication has 51 references indexed in Scilit:
- Task-Free Functional MRI in Cervical Dystonia Reveals Multi-Network Changes That Partially Normalize with Botulinum ToxinPLOS ONE, 2013
- Anatomical correlates of blepharospasmTranslational Neurodegeneration, 2012
- Changes in resting‐state brain networks in writer's crampHuman Brain Mapping, 2011
- Spasmodic dysphonia and botulinum toxin: experience from the largest treatment seriesEuropean Journal of Neurology, 2010
- Abnormal Activation of the Primary Somatosensory Cortex in Spasmodic Dysphonia: An fMRI StudyCerebral Cortex, 2010
- Sustained attention in cranial dystonia patients treated with botulinum toxinActa Neurologica Scandinavica, 2007
- White matter abnormalities in dystonia normalize after botulinum toxin treatmentNeuroReport, 2006
- Selective impairment of hand mental rotation in patients with focal hand dystoniaBrain, 2005
- Change in lateralization of the P22/N30 cortical component of median nerve somatosensory evoked potentials in patients with cervical dystonia after successful treatment with botulinum toxin AMovement Disorders, 1998
- Botulinum toxin does not reverse the cortical dysfunction associated with writer's cramp. A PET studyBrain, 1997